Saltar al contenido
Merck
  • [A case of iatrogenic immunodeficiency-associated lymphoproliferative disease in a patient treated with methotrexate for rheumatoid arthritis for 9 consecutive years, which Showed natural remission after discontinuation of MTX therapy].

[A case of iatrogenic immunodeficiency-associated lymphoproliferative disease in a patient treated with methotrexate for rheumatoid arthritis for 9 consecutive years, which Showed natural remission after discontinuation of MTX therapy].

Gan to kagaku ryoho. Cancer & chemotherapy (2014-01-08)
Jun Kaneko, Kazuo Gozu, Haruhiko Aoyagi, Toshihiro Matsui, Tsuyoshi Yoshida, Kumi Hasegawa, Jun Isogai, Shizuaki Maejima
RESUMEN

We report our experience with a case of iatrogenic immunodeficiency-associated lymphoproliferative disease in a patient who had been treated with methotrexate (MTX) for rheumatoid arthritis for 9 consecutive years, which showed natural remission after discontinuation of the MTX therapy. The patient was a 64-year-old woman who was admitted emergently to our hospital with hematemesis and melena. She presented with multiple gastric ulcers and bilateral tonsillitis with a central ulcer. Biopsy of these lesions raised the suspicion of diffuse large B-cell lymphoma. Positron emission tomography (PET)- computed tomography( CT) showed increased fluorodeoxyglucose( FDG) accumulation in the pharynx, cervical lymph nodes, liver, spleen, stomach, distal part of the ileum, and para-aortic lymph nodes, with a maximum standard uptake value of 26.85. Blood test showed elevated lactate dehydrogenase( LDH)( 321 U/L) and interleukin( IL)-2R( 3,531 U/mL) levels. After discontinuation of MTX, the sore throat subsided, and the tonsillitis, lymph node enlargement, and ulcers were resolved. The levels of LDH and IL-2R returned to within the normal range. The patient could be categorized into a regressive disease group with relatively favorable prognosis among patients with MTX-induced lymphoproliferative disease. However, she should continue to be followed up regularly because there remains a possibility that lymphoproliferative disease may relapse after the discontinuation of MTX.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Metotrexato hydrate, ≥98% (HPLC), powder
En este momento no podemos mostrarle ni los precios ni la disponibilidad
Sigma-Aldrich
Metotrexato hydrate, powder, BioReagent, suitable for cell culture, ≥98% (HPLC)
En este momento no podemos mostrarle ni los precios ni la disponibilidad
Sigma-Aldrich
Metotrexato hydrate, meets USP testing specifications
En este momento no podemos mostrarle ni los precios ni la disponibilidad
Methotrexate, European Pharmacopoeia (EP) Reference Standard
En este momento no podemos mostrarle ni los precios ni la disponibilidad
Sigma-Aldrich
Metotrexato hydrate, ≥99.0% (sum of enantiomers, HPLC)
En este momento no podemos mostrarle ni los precios ni la disponibilidad
Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard
En este momento no podemos mostrarle ni los precios ni la disponibilidad